Leo Wealth LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Leo Wealth LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,011 shares of the biopharmaceutical company’s stock after acquiring an additional 108 shares during the quarter. Leo Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $1,063,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Brown Lisle Cummings Inc. grew its position in shares of Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10 shares during the period. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Adirondack Trust Co. increased its stake in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares during the last quarter. Finally, Team Hewins LLC grew its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 11 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $17.88 on Tuesday, reaching $950.62. The stock had a trading volume of 1,001,464 shares, compared to its average volume of 500,208. The stock has a market cap of $104.80 billion, a P/E ratio of 24.91, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The business’s 50-day moving average price is $1,106.52 and its 200 day moving average price is $1,041.24. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Piper Sandler increased their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Finally, JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $1,116.00.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.